FDA Approves First Gene Therapy for Broad SMA Patient Population
The U.S. Food and Drug Administration (FDA) has approved Novartis’ Itvisma® (onasemnogene abeparvovec-brve) for children aged two years and older, as well as teens and adults, living…
Read More...
Read More...
